Standardization Roadmap
Project ScopeNeed/Challenge Need ID 0030. Currently, the SEND standard allows for the submission of general tox and carc studies in electronic standardized format. However, there are additional study types that are generally received that have not been standardized. There is a need to develop a strategy on how to plan, maximize, and transform standardization efforts. This plan should take into account resources, complexity, timeline and new approaches and technologies. Data gaps have been identified for many assessments, including Safety Pharm, Repro, Genetox, hERG, Animal Rule/MCM, Receptor Screen, and Device combination. Additionally, drug metadata can be better utilized so that, for example, Lot and Impurity information can be linked to study data, class, structure. Study Metadata represents another challenge. Information on protocol-related info + deviations, regulatory interpretation, sponsor interpretation, and regulatory information can be structured and linked so that information for a single study or across studies is more accessible. Vision Availability of useful electronic meta- and study data to enable more effective and efficient review of nonclinical data by both industry and regulatory reviewers. Data should be accessible to further investigate class effects and address regulatory science questions. |
Deliverable | Link |
---|---|
Poster CSS 2015 | SDTM customized to nonclinical data using a streamlined process.pdf |
How to build a custom domain resource | How to build a custom domain resource |
Ocular Irritation Custom Domain | Ocular Irritation Custom Domain |
Micronucleus Custom Domain | Micronucleus Custom Domain |
Motor Activity Custom Domain | Motor Activity Custom Domain |
Poster CSS 2014 | How to Design a SDTM Custom Domain for Nonclinical Data.pptx |
e-Paper | "The Roadmap for Nonclinical Data Standards and Elements to Improve Data Access" |
Poster CSS 2013 | Priorities in Nonclinical Data CSS2013.ppt |
Plans |
---|
Identified Projects/Pilots/Activities March 2014 - March 2015
March 2013 - March 2014
March 2012 - March 2013
|
Tasks |
---|
Accomplished
a) Identifies priorities in nonclinical study types and elements that enhance data utility, and b) Provides considerations for standards implementation and optimization Communication of the CDISC SEND team roadmap/goals (via Advance Hub) Planned
|
Milestones |
---|
March 2012 to March 2013
4 month
7 month
9 month
March 2013 to March 2014
5 month
7 month
9 month
11 month
|
Deliverables |
---|
March 2014 - March 2015
March 2013 - March 2014
March 2012 - March 2013
|
Participation Needs |
---|
A vast number of stakeholders will be impacted by the transformation and implementation of data standards. As the impact will be broad, we need representation from people with diverse backgrounds to join and actively participate in this group. A broad representation from the pharmaceutical industry, contract research organisations, software vendors and other stakeholders in data standardisation and eventually regulatory submissions will ensure the most complete and robust picture for the industry and the regulators to align to going forward.
Member Commitment
|
Disclaimer |
---|
FDA comments are an informal communication and represent the individual's best judgment. These comments do not bind or obligate FDA. The contents of this wiki are from the individual contributors and do not necessarily reflect the view and/or policies of the Food and Drug Administration, the employers of the individuals involved or any of their staff. |